---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-010227"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2024-02-06T23:59:59+00:00"
generated_at: "2026-06-06T08:32:17.148202+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# PBAX amends merger agreement with CERo, secures $2M PIPE, and target qualifies for potential $4-6M grant

## Summary
- Amendment to BCA removes minimum cash condition, resets earnout price targets based on Series A conversion price, and increases shares issuable to CERo stockholders from ~4.65M to 5.0M shares.
- PIPE financing of $2.0M from accredited investor in exchange for Series A Preferred Stock and warrants to purchase 125,000 shares; closing contingent on business combination.
- CERo selected as finalist for $4-6M subsidized grant from Cancer Focus Fund at MD Anderson for CER-1236 trial in AML; grant is not assured.
- PIPE securities issued in reliance on Section 4(a)(2) and Rule 506 of Regulation D; not registered under Securities Act.

## SEC filing metadata
- accession: 0001213900-24-010227
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2024-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390024010227/0001213900-24-010227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390024010227/ea192779-8k425_phoenix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-010227
- JSON: https://secwatch.observer/filing/0001213900-24-010227.json
- Plain text: https://secwatch.observer/filing/0001213900-24-010227.txt

## Key facts
- Material Agreements
  CERO THERAPEUTICS HOLDINGS, INC. entered into Securities Purchase Agreement with an accredited investor valued at $2.0 million (effective 2024-02-05).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an accredited investor
  - Value: $2.0 million
  - Effective: 2024-02-05
  source text: On February 5, 2024, the Company entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with an accredited investor
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390024010227/0001213900-24-010227-index.htm
- Material Agreements
  CERO THERAPEUTICS HOLDINGS, INC. amended Amendment No. 1 to the Business Combination Agreement with Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc. and CERo Therapeutics, Inc. (effective 2024-02-05).
  - Action: amendment
  - Agreement: merger
  - Counterparty: Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc. and CERo Therapeutics, Inc.
  - Effective: 2024-02-05
  source text: arties entered into Amendment No. 1 to the Business Combination Agreement (the “ Amendment ”) to, among other things, (i) remove the minimum cash condition, (ii) modify the stock-price based milestones such that (a) the trading price condition for the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390024010227/0001213900-24-010227-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.